News
- Author:
- Nancy A. Melville
Publish date: September 25, 2023
“Although the efficacy of the high tirzepatide dose might make it a favorable choice, its real-world application can be affected on an individual’s...
News
- Author:
- Nancy A. Melville
Publish date: September 20, 2023
“Probably the greatest concern shared by the writing group on this statement was the potential for clinicians to start ablation practices without h...
News
- Author:
- Nancy A. Melville
Publish date: September 7, 2023
The correlation between BCR-free survival and overall survival ranged from low to moderate.
News
- Author:
- Nancy A. Melville
Publish date: August 31, 2023
About one in five cancer survivors report experiencing financial toxicity, but financial monitoring is not a routine part of clinical care.
News
- Author:
- Nancy A. Melville
Publish date: August 31, 2023
The subcutaneous drug concizumab could be an important first treatment for hemophilia B with inhibitors; FDA resubmission is planned.
News
- Author:
- Nancy A. Melville
Publish date: August 24, 2023
After donor stem cell transplants, children with lower gut microbiota diversity show poorer survival and more complications.
News
- Author:
- Nancy A. Melville
Publish date: August 23, 2023
The authors speculate that caffeine could potentially affect thyroid activity by affecting pituitary function.
News
- Author:
- Nancy A. Melville
Publish date: August 21, 2023
Nationwide study on sickle cell disease shows life expectancy remains shortened in adulthood, though improved for child patients.
News
- Author:
- Nancy A. Melville
Publish date: August 15, 2023
Women identifying as sexual minorities show increases in postpartum depression, yet rates of reporting sexual orientation are low.
News
- Author:
- Nancy A. Melville
Publish date: August 8, 2023
In translational research that shows potential for humans, an antibody blockade of the Notch signaling pathway prevents graft-versus-host-disease i...
News
- Author:
- Nancy A. Melville
Publish date: July 25, 2023
“This meta-analysis is the first that generates evidence from randomized controlled trials to assess the association of vegetarian diets with outco...
News
- Author:
- Nancy A. Melville
Publish date: July 24, 2023
The ongoing debate over the use of LT3/LT4 combination therapy has persisted for more than 2 decades.
News
- Author:
- Nancy A. Melville
Publish date: July 24, 2023
The broader aim of developing the tool is for this new approach to be “applicable for developing future prognostic models of cancer and noncancer a...
News
- Author:
- Nancy A. Melville
Publish date: July 18, 2023
The FLT-inhibitor drug shows survival benefits in patients with higher-risk FLT3 mutations, with or without prior stem cell transplant.
News
- Author:
- Nancy A. Melville
Publish date: July 10, 2023
Phase 3 results suggest potential for a “functional cure”; this treatment could become first-ever approved CRISPR gene-editing therapy.
